Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna, Ipsen Ink RNAi Drug-Discovery Deal

Premium

Dicerna Pharmaceuticals said this week that it has signed a deal with French biotechnology firm Ipsen to develop RNAi-based therapeutics in the areas of oncology and endocrinology.

Under the terms of the deal, the companies will combine Dicerna's Dicer-substrate technology with Ipsen's peptide-based targeting vectors, which they said will allow cell-specific, intracellular delivery of the RNAi molecules.

Although the arrangement is focused on drug discovery, "Dicerna and Ipsen may collaborate further to move the programs discovered under this partnership into development and eventual commercialization," they noted.

Specific terms of the arrangement were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more